The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
Geraldine Gebhart
Research Funding - Roche (I)
Laetitia E. Lamberts
No relevant relationships to disclose
Camilo Garcia
No relevant relationships to disclose
Lieveke Ameye
No relevant relationships to disclose
Sigrid Stroobants
No relevant relationships to disclose
Manon Huizing
No relevant relationships to disclose
Philippe G. Aftimos
No relevant relationships to disclose
Jolien Tol
No relevant relationships to disclose
Wim J.G. Oyen
Research Funding - Roche/Genentech
Zena Wimana
No relevant relationships to disclose
G.A.M.S. van Dongen
No relevant relationships to disclose
Otto S. Hoekstra
No relevant relationships to disclose
Carolien P. Schroder
No relevant relationships to disclose
Julie Gaye
No relevant relationships to disclose
Catharina Wilhelmina Menke
No relevant relationships to disclose
Thomas Guiot
No relevant relationships to disclose
Adrienne H. Brouwers
No relevant relationships to disclose
Ahmad Awada
No relevant relationships to disclose
Elisabeth G. E. de Vries
Research Funding - Roche/Genentech
Patrick Flamen
Research Funding - Roche/Genentech